Olaparib in Patients With HRD Malignant Mesothelioma

  • Interventional
  • Recruiting
  • NCT04515836

Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma

In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.